CAPLIN POINT LABORATORIES LTD.

Caplin Point Laboratories Ltd has announced that its Board of Directors will convene on November 12, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. These results will be presented on both a standalone and consolidated basis. The company is also observing a trading window closure for designated persons from October 1, 2026, to November 14, 2026, in compliance with SEBI regulations.

Caplin Point Laboratories Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 01, 2026, and is in connection with the finalization of the unaudited financial results for the quarter and half-year ending September 30, 2026. The trading window will be reopened 48 hours after the financial results are officially declared to the stock exchanges. This measure aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct to prevent insider trading.

Caplin Point Laboratories Ltd has responded to BSE's query regarding a significant increase in its equity share trading volume. The company stated that it has made all requisite disclosures as per SEBI LODR Regulations and has not withheld any material or price-sensitive information. Caplin Point confirmed that the surge in trading volume is purely market-driven and they are not aware of any specific reasons contributing to it. The company reiterated its commitment to complying with all applicable disclosure requirements.

Caplin Point Laboratories Ltd has informed the stock exchanges about the dispatch of the Notice for its 35th Annual General Meeting (AGM) and the Annual Report for the financial year 2025-26. This communication is being sent to shareholders who have not registered their email addresses, providing a weblink to access these documents. The AGM is scheduled to be held on September 25, 2026, via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company encourages shareholders to update their email addresses for future communications.

Caplin Point Laboratories Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The report covers the company and its subsidiaries, Caplin Steriles Limited and Caplin One Labs Limited, focusing on manufacturing and sale of pharmaceuticals, which accounts for 100% of its turnover. The company has obtained limited assurance on its BRSR Core disclosures from M/s Alagar & Associates LLP. The report details corporate identity, operational locations, and business activities.

Caplin Point Laboratories Ltd has announced its 35th Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 10:00 AM IST via Video Conferencing/Other Audio Visual Means. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, declaration of a final dividend of ₹4 per share, and ratification of an interim dividend of ₹4 per share, totaling ₹8 per share. The AGM will also address the re-appointment of Dr. Sridhar Ganesan, who retires by rotation, and his re-appointment as Managing Director for a two-year term with a remuneration package including an annual salary of ₹55,20,000.

Caplin Point Laboratories Ltd announced its Annual Report for FY26, highlighting robust financial performance. Revenue grew 12.89% to ₹2,187 Crores, with net profit surging 20.08% to ₹650 Crores. The company emphasized a decade-long pattern of profit compounding at approximately 27% without debt funding. Key developments include Caplin Steriles USA achieving profitability in its first year, backward integration, and expansion plans in Mexico and Guatemala. Free cash reserves stand at ₹1,471 Crores, showing 21X growth over the decade. The 35th Annual General Meeting is scheduled for September 25, 2026.

Caplin Point Laboratories Ltd announced that its subsidiary, Caplin Steriles Limited, has completed an unannounced inspection by the United States Food and Drug Administration (US FDA) at its injectable and ophthalmic manufacturing facility in Gummidipoondi. The inspection, conducted from August 13 to August 21, 2026, resulted in the company receiving Form 483 with 10 observations. Caplin Point stated that these observations are procedural and do not pertain to data integrity, nor were they repeat observations. The company is actively addressing these points and will submit its response to the US FDA within the stipulated timeframe.

Caplin Point Laboratories Ltd announced board approval for the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from August 25, 2026, and the appointment of Mr. D. Muralidharan as Whole-Time Director for two years from August 12, 2026. Mr. Muralidharan will continue as CFO. Both appointments are subject to shareholder approval. Dr. Ganesan brings over 35 years of pharmaceutical leadership experience, while Mr. Muralidharan is a seasoned finance professional with extensive experience as CFO since 2016.

Caplin Point Laboratories Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors also recommended a Final Dividend of ₹4/- (200%) per equity share for the financial year ended March 31, 2026. Additionally, the company approved the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director. The 35th Annual General Meeting is scheduled for September 25, 2026.